QQ客服 官方微博 反馈留言

浏览/检索结果: 共10条，第1-10条 帮助 已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold 期刊论文 JOURNAL OF MEDICINAL CHEMISTRY, 2021, 卷号: 64, 期号: 9, 页码: 6161-6178 作者:  Xiong, Chaodong;  Zhou, Lina;  Tan, Jing;  Song, Shanshan;  Bao, Xubin 收藏  |  浏览/下载：32/0  |  提交时间：2021/08/17 SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met 期刊论文 CANCER SCIENCE, 2019, 页码: 11 作者:  Tong, Mengya;  Gao, Mingzhao;  Xu, Yongping;  Fu, Li;  Li, Yun 收藏  |  浏览/下载：21/0  |  提交时间：2020/07/01 AZD9291  c-Met ADC  c-Met overexpression  resistance  SHR-A1403   Pharmacological characterization of TQ05310, a potent inhibitor of isocitrate dehydrogenase 2 R140Q and R172K mutants 期刊论文 CANCER SCIENCE, 2019, 页码: 9 作者:  Gao, Mingzhao;  Zhu, Hongmei;  Fu, Li;  Li, Yun;  Bao, Xubin 收藏  |  浏览/下载：17/0  |  提交时间：2020/07/01 AG-221  IDH2  leukemia  R140Q  R172K   Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, invitro and in human tumor xenograft models 期刊论文 CANCER SCIENCE, 2019, 卷号: 110, 期号: 4, 页码: 1420-1430 作者:  Long, Fei;  He, Ye;  Fu, Haoyu;  Li, Yun;  Bao, Xubin 收藏  |  浏览/下载：20/0  |  提交时间：2020/07/01 breast cancer  CDK 4/6  drug resistance  palbociclib  SHR6390   Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials 期刊论文 CANCER SCIENCE, 2019, 卷号: 110, 期号: 3, 页码: 1064-1075 作者:  Wang, Lei;  Yang, Changyong;  Xie, Chengying;  Jiang, Jiahua;  Gao, Mingzhao 收藏  |  浏览/下载：22/0  |  提交时间：2020/07/01 antitumor activity  fluzoparib  pharmacokinetics  poly(ADP-ribose) polymerase  toxicity   Pharmacologic characterization of fluzoparib, a novel poly polymerase inhibitor undergoing clinical trials 期刊论文 Cancer Science, 2019, 卷号: Vol.110 No.3, 页码: 1064-1075 作者:  Lei Wang;  Changyong Yang;  Chengying Xie;  Jiahua Jiang;  Mingzhao Gao 收藏  |  浏览/下载：12/0  |  提交时间：2019/12/13 antitumor activity  fluzoparib  pharmacokinetics  poly(ADP‐ribose) polymerase  toxicity   Preclinical characterization of SHR6390, a novel CDK 4/6 inhibitor, in vitro and in human tumor xenograft models. 期刊论文 Cancer science, 2019 作者:  Fei Long;  Ye He;  Haoyu Fu;  Yun Li;  Xubin Bao 收藏  |  浏览/下载：22/0  |  提交时间：2019/12/17 CDK  4/6  SHR6390  breast  cancer  drug  resistance  palbociclib   Pharmacologic Characterization of Fluzoparib, a Novel Poly polymerase Inhibitor Undergoing Clinical Trials. 期刊论文 Cancer science, 2019 作者:  Lei Wang;  Changyong Yang;  Chengying Xie;  Jiahua Jiang;  Mingzhao Gao 收藏  |  浏览/下载：14/0  |  提交时间：2019/12/13 PARP  Antitumor  activity  Fluzoparib  Pharmacokinetics  Toxicity   Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist 期刊论文 JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 卷号: 22, 期号: 11, 页码: 5367-5377 作者:  Xie, Chengying;  Zhao, Huajun;  Bao, Xubin;  Fu, Haoyu;  Lou, Liguang 收藏  |  浏览/下载：34/0  |  提交时间：2019/01/08 eltrombopag  hetrombopag  hollow-fibre assay  thrombopoietin  thrombopoietin receptor   Combined inhibition of PI3K delta and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia 期刊论文 CANCER LETTERS, 2018, 卷号: 420, 页码: 49-59 作者:  He, Ye;  Sun, Liping;  Xu, Yongping;  Fu, Li;  Li, Yun 收藏  |  浏览/下载：34/0  |  提交时间：2019/01/08 Acute myeloid leukemia  FLT3  PI3K delta  CAL101  Synergistic effect